Rising plasma nociceptin level during development of HCC

A case report

Andrea Horvath, Aniko Folhoffer, P. Lakatos, J. Halász, G. Illyés, Z. Schaff, M. Hantos, K. Tekes, F. Szalay

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aim: Although liver cirrhosis is a predisposing factor for hepatocellular carcinoma (HCC), relatively few reports are available on HCC in primary biliary cirrhosis. High plasma nociceptin (N/OFQ) level has been shown in Wilson disease and in patients with acute and chronic pain. Methods: We report a follow-up case of HCC, which developed in a patient with primary biliary cirrhosis. The tumor appeared 18 years after the diagnosis of PBC and led to death within two years. Alfa fetoprotein and serum nociceptin levels were monitored before and during the development of HCC. Nociceptin content was also measured in the tumor tissue. Results: The importance and the curiosity of the presented case was the novel finding of the progressive elevation of plasma nociceptin level up to 17-fold (172 pg/mL) above the baseline (9.2±1.8 pg/mL), parallel with the elevation of alpha fetoprotein (from 13 ng/mL up to 3 480 ng/mL) during tumor development. Nociceptin content was more than 15-fold higher in the neoplastic tissue (0.16 pg/mg) than that in the tumor-free liver tissue samples (0.01 pg/mg) taken during the autopsy. Conclusion: Results are in concordance with our previous observation that a very high plasma nociceptin level may be considered as an indicator for hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)152-154
Number of pages3
JournalWorld Journal of Gastroenterology
Volume10
Issue number1
Publication statusPublished - Jan 2004

Fingerprint

Hepatocellular Carcinoma
Biliary Liver Cirrhosis
alpha-Fetoproteins
Neoplasms
Hepatolenticular Degeneration
Exploratory Behavior
Acute Pain
Chronic Pain
Liver Cirrhosis
Causality
nociceptin
Autopsy
Liver
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Rising plasma nociceptin level during development of HCC : A case report. / Horvath, Andrea; Folhoffer, Aniko; Lakatos, P.; Halász, J.; Illyés, G.; Schaff, Z.; Hantos, M.; Tekes, K.; Szalay, F.

In: World Journal of Gastroenterology, Vol. 10, No. 1, 01.2004, p. 152-154.

Research output: Contribution to journalArticle

@article{0cff190a5b1b407d8fd2f549b7af2b1e,
title = "Rising plasma nociceptin level during development of HCC: A case report",
abstract = "Aim: Although liver cirrhosis is a predisposing factor for hepatocellular carcinoma (HCC), relatively few reports are available on HCC in primary biliary cirrhosis. High plasma nociceptin (N/OFQ) level has been shown in Wilson disease and in patients with acute and chronic pain. Methods: We report a follow-up case of HCC, which developed in a patient with primary biliary cirrhosis. The tumor appeared 18 years after the diagnosis of PBC and led to death within two years. Alfa fetoprotein and serum nociceptin levels were monitored before and during the development of HCC. Nociceptin content was also measured in the tumor tissue. Results: The importance and the curiosity of the presented case was the novel finding of the progressive elevation of plasma nociceptin level up to 17-fold (172 pg/mL) above the baseline (9.2±1.8 pg/mL), parallel with the elevation of alpha fetoprotein (from 13 ng/mL up to 3 480 ng/mL) during tumor development. Nociceptin content was more than 15-fold higher in the neoplastic tissue (0.16 pg/mg) than that in the tumor-free liver tissue samples (0.01 pg/mg) taken during the autopsy. Conclusion: Results are in concordance with our previous observation that a very high plasma nociceptin level may be considered as an indicator for hepatocellular carcinoma.",
author = "Andrea Horvath and Aniko Folhoffer and P. Lakatos and J. Hal{\'a}sz and G. Illy{\'e}s and Z. Schaff and M. Hantos and K. Tekes and F. Szalay",
year = "2004",
month = "1",
language = "English",
volume = "10",
pages = "152--154",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "1",

}

TY - JOUR

T1 - Rising plasma nociceptin level during development of HCC

T2 - A case report

AU - Horvath, Andrea

AU - Folhoffer, Aniko

AU - Lakatos, P.

AU - Halász, J.

AU - Illyés, G.

AU - Schaff, Z.

AU - Hantos, M.

AU - Tekes, K.

AU - Szalay, F.

PY - 2004/1

Y1 - 2004/1

N2 - Aim: Although liver cirrhosis is a predisposing factor for hepatocellular carcinoma (HCC), relatively few reports are available on HCC in primary biliary cirrhosis. High plasma nociceptin (N/OFQ) level has been shown in Wilson disease and in patients with acute and chronic pain. Methods: We report a follow-up case of HCC, which developed in a patient with primary biliary cirrhosis. The tumor appeared 18 years after the diagnosis of PBC and led to death within two years. Alfa fetoprotein and serum nociceptin levels were monitored before and during the development of HCC. Nociceptin content was also measured in the tumor tissue. Results: The importance and the curiosity of the presented case was the novel finding of the progressive elevation of plasma nociceptin level up to 17-fold (172 pg/mL) above the baseline (9.2±1.8 pg/mL), parallel with the elevation of alpha fetoprotein (from 13 ng/mL up to 3 480 ng/mL) during tumor development. Nociceptin content was more than 15-fold higher in the neoplastic tissue (0.16 pg/mg) than that in the tumor-free liver tissue samples (0.01 pg/mg) taken during the autopsy. Conclusion: Results are in concordance with our previous observation that a very high plasma nociceptin level may be considered as an indicator for hepatocellular carcinoma.

AB - Aim: Although liver cirrhosis is a predisposing factor for hepatocellular carcinoma (HCC), relatively few reports are available on HCC in primary biliary cirrhosis. High plasma nociceptin (N/OFQ) level has been shown in Wilson disease and in patients with acute and chronic pain. Methods: We report a follow-up case of HCC, which developed in a patient with primary biliary cirrhosis. The tumor appeared 18 years after the diagnosis of PBC and led to death within two years. Alfa fetoprotein and serum nociceptin levels were monitored before and during the development of HCC. Nociceptin content was also measured in the tumor tissue. Results: The importance and the curiosity of the presented case was the novel finding of the progressive elevation of plasma nociceptin level up to 17-fold (172 pg/mL) above the baseline (9.2±1.8 pg/mL), parallel with the elevation of alpha fetoprotein (from 13 ng/mL up to 3 480 ng/mL) during tumor development. Nociceptin content was more than 15-fold higher in the neoplastic tissue (0.16 pg/mg) than that in the tumor-free liver tissue samples (0.01 pg/mg) taken during the autopsy. Conclusion: Results are in concordance with our previous observation that a very high plasma nociceptin level may be considered as an indicator for hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0347287012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347287012&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 152

EP - 154

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 1

ER -